Onorach Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Onorach Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014289
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Onorach Ltd (Onorach) is a contract research organization that provides clinical support services. The organization service portfolio includes tailored clinical trial support, clinical plan development, protocol design, regulatory, quality management, clinical operations management, patient and subject recruitment, project management, clinical monitoring, statistical analysis and medical report writing services among others. Onorach also provides temperature monitoring, stability testing, drug supplying, placebo sourcing, labeling, packaging, distribution, and pre-clinical and specialized lipid analysis services. The organization’s target therapy areas include cardiovascular, cell based therapeutics, CNS, neurology, endocrinology, infectious diseases, oncology, pediatricians, women’s health, and other therapeutics areas. It caters to pharmaceutical, biotech and medical device companies. Onorach is headquartered in Dundee, the UK.

Onorach Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Onorach Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Onorach Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Epirus Biopharma Raises US$36 Million In Series B Venture Financing 13
EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 15
EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 16
Private Equity 17
BioGeneration Ventures, Thuja Capital and Forbion Capital Partners Divest Bioceros 17
Partnerships 18
Polpharma Enters into Agreement with Epirus Biopharma 18
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 19
Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 20
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 21
Licensing Agreements 22
Livzon Mabpharm Amends its Licensing Agreement with Epirus Biopharma 22
Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 24
Epirus Enters Into Licensing Agreement With Ranbaxy Labs For BOW015 25
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 26
Bioceros Expands Licensing Agreement With Crucell 27
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research 28
Equity Offering 29
Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 29
Epirus Biopharma Raises USD53 Million in Public Offering of Shares 30
Zalicus Completes First Tranche Of Private Placement Of Shares For US$2 Million 31
Zalicus Completes Public Offering Of Shares For US$15 Million 32
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$9 Million 33
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$4.25 Million 34
Asset Transactions 35
Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 35
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 36
Acquisition 37
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 37
Taro Pharma Acquires Zalicus Pharma 39
Epirus Biopharma Acquires Bioceros for USD14 Million 40
Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 41
Onorach Ltd – Key Competitors 43
Onorach Ltd – Key Employees 44
Onorach Ltd – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Onorach Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Onorach Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Onorach Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Onorach Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Onorach Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Onorach Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Epirus Biopharma Raises US$36 Million In Series B Venture Financing 13
EPIRUS Biopharmaceuticals Secures USD5 Million in Venture Funding 15
EPIRUS Biopharmaceuticals Secures USD8.08 Million in Venture Funding 16
BioGeneration Ventures, Thuja Capital and Forbion Capital Partners Divest Bioceros 17
Polpharma Enters into Agreement with Epirus Biopharma 18
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 19
Epirus Enters Into Co-Development Agreement With Orygen Biotecnologia 20
Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain 21
Livzon Mabpharm Amends its Licensing Agreement with Epirus Biopharma 22
Zalicus Enters into Licensing Agreement with AnaBios for Sodium Channel Pain Modulation Program 24
Epirus Enters Into Licensing Agreement With Ranbaxy Labs For BOW015 25
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 26
Bioceros Expands Licensing Agreement With Crucell 27
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research 28
Epirus Biopharma to Raise up to USD30 Million in Public Offering of Shares 29
Epirus Biopharma Raises USD53 Million in Public Offering of Shares 30
Zalicus Completes First Tranche Of Private Placement Of Shares For US$2 Million 31
Zalicus Completes Public Offering Of Shares For US$15 Million 32
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$9 Million 33
Zalicus Completes Second Tranche Of Private Placement Of Shares For US$4.25 Million 34
Reliance Life Sciences Acquires Global Rights of Infliximab from EPIRUS Biopharma 35
Horizon Discovery Completes Acquisition of Combination High Throughput Screening from Zalicus 36
Polpharma to Acquire EPIRUS Netherlands from EPIRUS Biopharma 37
Taro Pharma Acquires Zalicus Pharma 39
Epirus Biopharma Acquires Bioceros for USD14 Million 40
Epirus Biopharma Acquires Zalicus in Reverse Takeover Transaction 41
Onorach Ltd, Key Competitors 43
Onorach Ltd, Key Employees 44
Onorach Ltd, Subsidiaries 45

★海外企業調査レポート[Onorach Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Compagnie d’Entreprises CFE SA:企業の戦略・SWOT・財務情報
    Compagnie d'Entreprises CFE SA - Strategy, SWOT and Corporate Finance Report Summary Compagnie d'Entreprises CFE SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Primary Health Care Ltd (PRY):企業の財務・戦略的SWOT分析
    Primary Health Care Ltd (PRY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • SREI Infrastructure Finance Ltd:企業のM&A・事業提携・投資動向
    SREI Infrastructure Finance Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SREI Infrastructure Finance Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Ultragenyx Pharmaceutical Inc.:企業の戦略・SWOT・財務分析
    Ultragenyx Pharmaceutical Inc. - Strategy, SWOT and Corporate Finance Report Summary Ultragenyx Pharmaceutical Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • NR Electric Co Ltd:企業の戦略的SWOT分析
    NR Electric Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Noile-Immune Biotech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Noile-Immune Biotech Inc (Noile-Immune Biotech) is a clinical stage biotechnology company that develops and commercializes next generation CAR-T cell therapies for the treatment of cancer. The company works in collaboration with National Cancer Center Japan and Yamaguchi University to develo …
  • Maquet Holding BV & Co KG:企業の戦略的SWOT分析
    Maquet Holding BV & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Egmont International Holding AS:企業の戦略的SWOT分析
    Egmont International Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Ladbrokes plc:戦略・SWOT・企業財務分析
    Ladbrokes plc - Strategy, SWOT and Corporate Finance Report Summary Ladbrokes plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Brookfield Property REIT Inc (GGP):企業の財務・戦略的SWOT分析
    Brookfield Property REIT Inc (GGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Advent Capital (Holdings) Ltd:企業の戦略・SWOT・財務情報
    Advent Capital (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Advent Capital (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • PT. Millennium Pharmacon International TBK (SDPC):企業の財務・戦略的SWOT分析
    PT. Millennium Pharmacon International TBK (SDPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • TBG Diagnostics Ltd (TDL):医療機器:M&Aディール及び事業提携情報
    Summary TBG Diagnostics Ltd (TBG Diagnostics), formerly Progen Pharmaceuticals Ltd, is a molecular diagnostics company that develops, manufactures and markets molecular diagnostics kits, instruments and services. The company’s major products include nucleic acid extraction kits, HLA SBT typing kits, …
  • CapitalSource:企業の戦略・SWOT・財務情報
    CapitalSource - Strategy, SWOT and Corporate Finance Report Summary CapitalSource - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Foxconn Technology Co Ltd:企業の戦略・SWOT・財務分析
    Foxconn Technology Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Foxconn Technology Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • National Fuel Gas Company:企業の戦略・SWOT・財務情報
    National Fuel Gas Company - Strategy, SWOT and Corporate Finance Report Summary National Fuel Gas Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Oxurion NV (THR):製薬・医療:M&Aディール及び事業提携情報
    Summary Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreo …
  • Kenya Power and Lighting Co Ltd (KPLA):企業の財務・戦略的SWOT分析
    Kenya Power and Lighting Co Ltd (KPLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • FGL Sports Ltd.:企業の戦略・SWOT・財務情報
    FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report Summary FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆